Core Viewpoint - Shenzhen Keda Li Industrial Co., Ltd. has completed the industrial and commercial change registration for its wholly-owned subsidiary, Jiangsu Keda Li Precision Industry Co., Ltd., following a capital increase of 400 million yuan [1]. Group 1: Company Actions - The company approved the conversion of part of the fundraising loans into capital increase for Jiangsu Keda Li during board and shareholder meetings held on June 30, 2025, and September 2, 2025 [1]. - The capital increase amount is 400 million yuan, raising Jiangsu Keda Li's registered capital from 600 million yuan to 1 billion yuan [1]. Group 2: Subsidiary Information - Jiangsu Keda Li has completed the necessary industrial and commercial change registration, with the new registration details including a registered capital of 1 billion yuan and a legal representative named Li Wuzhang [1]. - The subsidiary's business scope includes manufacturing and sales of lithium battery structural parts, molds, hardware products, plastic products, and automotive parts, as well as logistics and import-export activities [1].

Core Viewpoint - The company is holding its third extraordinary general meeting of shareholders in 2025 to discuss several key proposals, including profit distribution, establishment of a wholly-owned subsidiary, capital increase for project implementation, and an employee stock ownership plan [1][5][9]. Proposal Summaries Proposal 1: Mid-Year Profit Distribution Plan - As of June 30, 2025, the company achieved a net profit attributable to shareholders of RMB 139,025,450.88, with distributable profits amounting to RMB 207,419,073.75. The proposed cash dividend is RMB 4.00 per 10 shares, totaling RMB 62,738,732.00, which represents 45.13% of the net profit for the first half of 2025 [6][7]. Proposal 2: Establishment of a Wholly-Owned Subsidiary - The company plans to invest RMB 100 million to establish a wholly-owned subsidiary, Suzhou Xidian New Energy Technology Co., Ltd., to independently develop its FCC workshop. This investment is not considered a related party transaction or a major asset restructuring [9][10]. Proposal 3: Capital Increase for Wholly-Owned Subsidiary - The company intends to use part of the raised funds to increase the capital of its wholly-owned subsidiary, Suzhou Xidian New Energy Vehicle Electronics Co., Ltd., by RMB 100 million, raising its registered capital from RMB 50 million to RMB 150 million. This is aimed at ensuring the smooth implementation of fundraising projects [12][13]. Proposal 4: Renewal of Audit Firm - The company proposes to renew its engagement with Rongcheng Accounting Firm, which has a long history in securities services and has audited 518 listed companies in 2024. The firm has a total revenue of RMB 251,025,800, with audit services contributing RMB 234,862,940 [14][15][19]. Proposal 5: Second Employee Stock Ownership Plan - The company aims to implement a second employee stock ownership plan to enhance the motivation of management and key employees, thereby promoting sustainable development. The plan has been reviewed and approved by the board [21][22].

Core Viewpoint - The company plans to increase capital for its subsidiary, Jiuzhou Pharmaceutical (Taizhou) Co., Ltd., using part of the raised funds from its non-public stock issuance, which has been approved by the board and supervisory committee without needing shareholder approval [1][7]. Group 1: Fundraising Overview - The company raised a total of approximately RMB 2.5 billion through a non-public issuance of 65,291,198 shares at a price of RMB 38.29 per share [2]. - The funds have been verified and stored in a dedicated account as per regulatory requirements [3][6]. Group 2: Capital Increase Details - The capital increase amount is set at RMB 200 million, which will raise the registered capital of Jiuzhou Pharmaceutical (Taizhou) from RMB 175 million to RMB 190 million [5]. - The capital surplus of RMB 185 million will be included in the capital reserve, and Jiuzhou Pharmaceutical (Taizhou) will remain a wholly-owned subsidiary of the company [5]. Group 3: Financial Data of Jiuzhou Pharmaceutical (Taizhou) - As of June 30, 2025, the total assets of Jiuzhou Pharmaceutical (Taizhou) were approximately RMB 1.54 billion, with liabilities of about RMB 610 million and net assets of around RMB 933 million [5]. - The company reported a revenue of approximately RMB 98.26 million for the first half of 2025, with a net loss of about RMB 28.35 million [5]. Group 4: Purpose and Impact of Capital Increase - The capital increase aims to meet the actual construction needs of the fundraising project without altering the investment direction or project content [7]. - This move is expected to enhance the efficiency of fund utilization and ensure the smooth implementation of the investment projects, aligning with the company's long-term strategic goals [7]. Group 5: Opinions from Supervisory and Sponsoring Institutions - The supervisory committee supports the capital increase, stating it aligns with the interests of the company and all shareholders [7]. - The sponsoring institution, Huatai United Securities, confirms that the capital increase complies with relevant regulations and does not affect the normal implementation of the investment projects [8].

Core Viewpoint - The company, Zhongke Hanwuji Technology Co., Ltd., held its 24th meeting of the second Supervisory Board on July 17, 2025, where several key resolutions were passed regarding the use of raised funds and adjustments to the stock issuance plan [1][2]. Group 1: Fund Utilization - The Supervisory Board approved the use of 100 million RMB of raised funds to increase the capital of its wholly-owned subsidiary, Shanghai Hanwuji Information Technology Co., Ltd., to support the implementation of financing projects [1][2]. - The board also agreed to allow the company and its subsidiary to use their own funds to pay for project expenses, which will later be replaced with an equivalent amount from the raised funds [2][3]. Group 2: Stock Issuance Adjustments - The board approved adjustments to the 2025 stock issuance plan, allowing the number of shares issued to be determined by the total amount raised divided by the issuance price, with a cap of 5% of the total share capital prior to the issuance [3][6]. - The maximum number of shares to be issued was adjusted from 20,872,837 shares to 20,917,511 shares due to an increase in total share capital following the completion of a stock incentive plan [3][4]. Group 3: Financial Projections - The total amount to be raised from the stock issuance was revised from a maximum of 4,980 million RMB to 3,985.3273 million RMB, with the net amount after deducting issuance costs intended for various projects [5][6]. - The company confirmed that the other parts of the stock issuance plan remain unchanged despite these adjustments [5][6]. Group 4: Reports and Analysis - The board approved several reports related to the revised stock issuance plan, including feasibility analysis and measures to address the dilution of immediate returns [7][8][9]. - The company also confirmed that the raised funds will be directed towards technology innovation, aligning with its strategic goals [9][10].

Group 1 - The company plans to use raised funds to increase capital for its subsidiary Henan Yuzhan by 725.65 million yuan, which will then be used to increase capital for Shenzhen Yuzhan by the same amount [1] - The purpose of this capital increase is to ensure the smooth implementation of fundraising projects, enhance the capital strength of the project implementation entity, and improve the efficiency of fund utilization [1] - This capital increase does not constitute a related party transaction or a major asset restructuring, and does not require approval from the shareholders' meeting [1]